论文部分内容阅读
目的观察曲美他嗪治疗冠心病的临床效果及安全性。方法选择冠心病心力衰竭患者60例,随机分为观察组和对照组各30例。对照组给予常规治疗,观察组在常规治疗的基础上给予曲美他嗪治疗,疗程3个月,观察两组患者的临床效果及不良反应。结果观察组的总有效率优于对照组的总有效率(P<0.05),2组治疗后左室射血分数观察组优于对照组(P<0.05),无严重不良反应。结论曲美他嗪治疗冠心病心力衰竭疗效满意,无严重不良反应。
Objective To observe the clinical effect and safety of trimetazidine in the treatment of coronary heart disease. Methods Sixty patients with coronary heart disease and heart failure were randomly divided into observation group and control group, 30 cases each. The control group was given routine treatment. The observation group was treated with trimetazidine on the basis of routine treatment for 3 months. The clinical effects and adverse reactions in both groups were observed. Results The total effective rate in the observation group was better than that in the control group (P <0.05). The left ventricular ejection fraction in the observation group was better than that in the control group (P <0.05) after treatment. There was no serious adverse reaction. Conclusion Trimetazidine treatment of coronary heart disease with satisfactory results, no serious adverse reactions.